We are live on
!
Find out more
SA
Shilanski & Associates Portfolio holdings
AUM
$376M
1-Year Est. Return
19.08%
This Fund
S&P 500
This Quarter
Est. Return
+2.08%
1 Year Est. Return
+19.08%
3 Year Est. Return
+84.25%
5 Year Est. Return
+122.72%
10 Year Est. Return
–
AUM
$297M
AUM Growth
+$6.95M
(+2.4%)
Cap. Flow
+$3M
Cap. Flow
% of AUM
1.01%
Top 10 Holdings %
Top 10 Hldgs %
43.22%
Holding
116
New
11
Increased
38
Reduced
55
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WisdomTree Trust WisdomTree US Quality Dividend Growth Fund
DGRW
|
+$2.52M |
| 2 |
Marathon Petroleum
MPC
|
+$1.12M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$847K |
| 4 |
Schwab US Broad Market ETF
SCHB
|
+$712K |
| 5 |
Solventum
SOLV
|
+$335K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.66M |
| 2 |
Qualys
QLYS
|
+$1.28M |
| 3 |
3M
MMM
|
+$768K |
| 4 |
Nucor
NUE
|
+$339K |
| 5 |
Apple
AAPL
|
+$281K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.28% |
| 2 | Consumer Staples | 8.36% |
| 3 | Financials | 5.83% |
| 4 | Industrials | 5.37% |
| 5 | Healthcare | 4.18% |
Similar funds
NELSF
MFGP
BCCM
PA
BWA
PAWA
CPA
AACP
Shilanski & Associates's Q2 2024 Portfolio in Review
As of Q2 2024, Shilanski & Associates held 116 positions worth $297M, up 2.4% from $290M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Shilanski & Associates's Q2 2024 filing shows 11 new, 38 increased, 55 reduced and 8 closed positions. Its largest new stake was WisdomTree Trust WisdomTree US Quality Dividend Growth Fund: 33,382 shares worth $2.61M. The largest sale was Pfizer, an estimated $2.66M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Financials.
- Shilanski & Associates's largest Q2 2024 buy was WisdomTree Trust WisdomTree US Quality Dividend Growth Fund: 33,382 shares worth $2.61M.
- Shilanski & Associates added most to State Street SPDR S&P 500 ETF Trust in Q2 2024, an estimated $847K increase.
- Shilanski & Associates's biggest Q2 2024 reduction was 3M, cutting an estimated $768K.
- Shilanski & Associates fully exited Pfizer in Q2 2024, selling an estimated $2.66M.
- Shilanski & Associates's ten largest holdings make up 43% of its $297M portfolio in Q2 2024.
- Shilanski & Associates opened 11 new positions and closed 8 in Q2 2024.
- Shilanski & Associates's portfolio value rose 2.4% quarter-over-quarter to $297M.
Based on Shilanski & Associates's 13F filing for Q2 2024, filed 18 Jul 2024.